Baicalin inhibits the lethality of Shiga-like toxin 2 in mice

Antimicrobial Agents and Chemotherapy
Jing DongXuming Deng

Abstract

Shiga-like toxins (Stxs), produced by pathogenic Escherichia coli, are a major virulence factor involved in severe diseases in human and animals. These toxins are ribosome-inactivating proteins, and treatment for diseases caused by them is not available. Therefore, there is an urgent need for agents capable of effectively targeting this lethal toxin. In this study, we identified baicalin, a flavonoid compound used in Chinese traditional medicine, as a compound against Shiga-like toxin 2 (Stx2). We found that baicalin significantly improves renal function and reduces Stx2-induced lethality in mice. Further experiments revealed that baicalin induces the formation of oligomers by the toxin by direct binding. We also identified the residues important for such interactions and analyzed their roles in binding baicalin by biophysical and biochemical analyses. Our results establish baicalin as a candidate compound for the development of therapeutics against diseases caused by Stxs.

References

Dec 1, 1982·The Journal of Infectious Diseases·A D O'BrienS B Formal
Jan 1, 1981·Chromosoma·J A SubiranaI Fita
Apr 16, 1998·The Journal of Infectious Diseases·L SlutskerP M Griffin
Jan 5, 2002·Journal of Medicinal Chemistry·Darcie J MillerJon D Robertus
Apr 18, 2002·Antimicrobial Agents and Chemotherapy·Ying Lan ZhaoTakaaki Hasegawa
Apr 13, 2004·The Journal of Biological Chemistry·Marie E FraserMichael N G James
Oct 19, 2004·Clinical Microbiology Reviews·Saul TziporiHoward Trachtman
Jun 20, 2006·Neurotoxicity Research·Lucie BartosovaDaniel Jun
Aug 22, 2007·Nature Chemical Biology·Anne E ClatworthyDeborah T Hung
Jan 29, 2011·Pediatric Research·Claudia SilbersteinCristina Ibarra
Sep 15, 2011·Current Topics in Microbiology and Immunology·Angela Melton-CelsaAlison O'Brien
Oct 19, 2011·Current Topics in Microbiology and Immunology·Paul G WahomeNicholas J Mantis
Apr 5, 2013·Clinical Microbiology Reviews·Alejandro BeceiroGermán Bou
Sep 10, 2013·Infectious Disease Clinics of North America·T Keefe DavisPhillip I Tarr
May 20, 2014·Journal of Nucleic Acids·Sreerupa ChallaAbhineet Sheoran
Apr 8, 2015·The Journal of Biological Chemistry·Jing DongXuming Deng

❮ Previous
Next ❯

Citations

Feb 6, 2016·Journal of the American Chemical Society·Lun K TsouHoward C Hang
Feb 16, 2018·Artificial Cells, Nanomedicine, and Biotechnology·Chun-Hsien LiYu-Chie Chen
Sep 22, 2019·Journal of Applied Microbiology·T RamiresW P da Silva
Mar 25, 2017·Frontiers in Microbiology·Yong ZhangXuming Deng
May 17, 2019·International Journal of Molecular Sciences·Shulin FuChien-An Andy Hu
May 28, 2019·FEMS Microbiology Letters·Shui LiuXuming Deng
Apr 21, 2017·Emerging Topics in Life Sciences·Alejandro Huerta-Uribe, Andrew J Roe

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.